


Data Sheet

Product Name:	Molnupiravir
Cat. No.:	CS-0114880
CAS No.:	2492423-29-5
Molecular Formula:	C ₁₃ H ₁₉ N ₃ O ₇
Molecular Weight:	329.31
Target:	Influenza Virus; SARS-CoV
Pathway:	Anti-infection
Solubility:	DMSO : 50 mg/mL (151.83 mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against **influenza virus** and multiple **coronaviruses**, such as **SARS-CoV-2**, **MERS-CoV**, **SARS-CoV**. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza^{[1][2]}. *In Vivo*: Molnupiravir (50-500 mg/kg; p.o.; every 12 hours for 3 days) is robustly antiviral and able to prevent SARS-CoV replication and disease^[1]. Molnupiravir (7 mg/kg; p.o.; twice daily for 3.5 days) significantly reduces shed virus load and duration of fever^[2].

References:

[1]. Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. *Sci Transl Med.* 2019 Oct 23;11(515). pii: eaax5866.

[2]. Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. *Sci Transl Med.* 2020 Apr 6. pii: eabb5883.

CAIndexNames:

((2R,3S,4R,5R)-3,4-Dihydroxy-5-(4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate

SMILES:

O=C(N([C@@]1([H])[C@H](O)[C@H](O)[C@@]1([H]))(COC(C(C)C)=O)O1)C=C2)NC2=NO

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA